"If you take the long view, five years or 10 years from now you're going to have multiple therapeutic options for patients who suffer from NASH – all, perhaps, with different mechanisms of action. Our hypothesis is that insulin resistance is a key trigger, so if we're successful, MSDC-0602K will become a cornerstone drug."
Bob Baltera, CEO of Cirius Therapeutics Inc., discussing the company's $40 million series A and ongoing phase IIb EMMINENCE trial of MSDC-0602K in NASH

"People only do risky things when there's a reward for doing it. There is a real downside for probing too harshly on this industry because I think it will reduce innovation."
Joanna Shepherd, a professor of law at Emory University School of Law and an expert on health policy

"We view Ingrezza's label as the best possible scenario and above expectations."
Jefferies Group LLC analyst Biren Amin, on the FDA approval of Neurocrine Biosciences Inc.'s selective vesicular monoamine transporter 2 inhibitor, Ingrezza (valbenazine), to treat adults with tardive dyskinesia